Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia

14 augusti 2017 uppdaterad av: GlaxoSmithKline

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia

This is a study consisting of four periods (screening, run-in, treatment, follow-up). A four-week treatment-free, run-in period where the subject will make at least four attempts at intercourse on four separate days with at least 50% of the attempts must be unsuccessful. During run-in the subjects will be using a stopwatch to measure the time from erection perceived hard enough for penetration until withdrawal from the partner's vagina. Next there are 12 weeks of treatment with either placebo or LEVITRA. Each subject will be required to visit the clinic on 5 occasions over a period of 4 months.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

395

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Alabama
      • Fairhope, Alabama, Förenta staterna, 36532
        • GSK Investigational Site
      • Homewood, Alabama, Förenta staterna, 35209
        • GSK Investigational Site
      • Huntsville, Alabama, Förenta staterna, 35801
        • GSK Investigational Site
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85016
        • GSK Investigational Site
      • Phoenix, Arizona, Förenta staterna, 85023
        • GSK Investigational Site
    • California
      • Concord, California, Förenta staterna, 94520
        • GSK Investigational Site
      • Huntington Park, California, Förenta staterna, 90255
        • GSK Investigational Site
      • Long Beach, California, Förenta staterna, 90806
        • GSK Investigational Site
      • Modesto, California, Förenta staterna, 95350
        • GSK Investigational Site
      • Newport Beach, California, Förenta staterna, 92660
        • GSK Investigational Site
      • Orangevale, California, Förenta staterna, 95662
        • GSK Investigational Site
      • Santa Ana, California, Förenta staterna, 92705
        • GSK Investigational Site
      • Walnut Creek, California, Förenta staterna, 94598
        • GSK Investigational Site
    • Colorado
      • Denver, Colorado, Förenta staterna, 80210
        • GSK Investigational Site
      • Wheat Ridge, Colorado, Förenta staterna, 80033
        • GSK Investigational Site
    • Connecticut
      • New Britain, Connecticut, Förenta staterna, 06052
        • GSK Investigational Site
    • Florida
      • Aventura, Florida, Förenta staterna, 33180
        • GSK Investigational Site
      • Clearwater, Florida, Förenta staterna, 33761
        • GSK Investigational Site
      • Coral Gables, Florida, Förenta staterna, 33134
        • GSK Investigational Site
      • Fort Myers, Florida, Förenta staterna, 33916
        • GSK Investigational Site
      • North Miami, Florida, Förenta staterna, 33161
        • GSK Investigational Site
      • Orlando, Florida, Förenta staterna, 32803
        • GSK Investigational Site
      • Pembroke Pines, Florida, Förenta staterna, 33024
        • GSK Investigational Site
      • Pinecrest, Florida, Förenta staterna, 33156
        • GSK Investigational Site
      • Saint Petersburg, Florida, Förenta staterna, 33710
        • GSK Investigational Site
      • Sarasota, Florida, Förenta staterna, 34237
        • GSK Investigational Site
      • South Miami, Florida, Förenta staterna, 33143
        • GSK Investigational Site
      • Tampa, Florida, Förenta staterna, 33607
        • GSK Investigational Site
      • West Palm Beach, Florida, Förenta staterna, 33401
        • GSK Investigational Site
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30342
        • GSK Investigational Site
      • Columbus, Georgia, Förenta staterna, 31904
        • GSK Investigational Site
      • Dawsonville, Georgia, Förenta staterna, 30534
        • GSK Investigational Site
      • Roswell, Georgia, Förenta staterna, 30076
        • GSK Investigational Site
      • Woodstock, Georgia, Förenta staterna, 30189
        • GSK Investigational Site
    • Indiana
      • Avon, Indiana, Förenta staterna, 46123
        • GSK Investigational Site
      • Evansville, Indiana, Förenta staterna, 47714
        • GSK Investigational Site
      • Fort Wayne, Indiana, Förenta staterna, 46825
        • GSK Investigational Site
      • Jeffersonville, Indiana, Förenta staterna, 47130
        • GSK Investigational Site
    • Kansas
      • Wichita, Kansas, Förenta staterna, 67207
        • GSK Investigational Site
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40509
        • GSK Investigational Site
      • Madisonville, Kentucky, Förenta staterna, 42431
        • GSK Investigational Site
    • Louisiana
      • Shreveport, Louisiana, Förenta staterna, 71106
        • GSK Investigational Site
    • Maine
      • Swansea, Maine, Förenta staterna, 02777
        • GSK Investigational Site
    • Massachusetts
      • Taunton, Massachusetts, Förenta staterna, 02780
        • GSK Investigational Site
    • Michigan
      • Kalamazoo, Michigan, Förenta staterna, 49009
        • GSK Investigational Site
    • Minnesota
      • Saint Louis Park, Minnesota, Förenta staterna, 55416
        • GSK Investigational Site
    • Missouri
      • Saint Louis, Missouri, Förenta staterna, 63117
        • GSK Investigational Site
    • Nebraska
      • Omaha, Nebraska, Förenta staterna, 68134
        • GSK Investigational Site
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89119
        • GSK Investigational Site
    • New Jersey
      • Lawrenceville, New Jersey, Förenta staterna, 08648
        • GSK Investigational Site
    • New York
      • New York, New York, Förenta staterna, 10016
        • GSK Investigational Site
      • Rochester, New York, Förenta staterna, 14609
        • GSK Investigational Site
      • West Seneca, New York, Förenta staterna, 14224
        • GSK Investigational Site
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28262
        • GSK Investigational Site
      • Fayetteville, North Carolina, Förenta staterna, 28304
        • GSK Investigational Site
      • Winston-Salem, North Carolina, Förenta staterna, 27103
        • GSK Investigational Site
    • Pennsylvania
      • Shippensburg, Pennsylvania, Förenta staterna, 17257
        • GSK Investigational Site
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • GSK Investigational Site
    • Texas
      • Amarillo, Texas, Förenta staterna, 79106
        • GSK Investigational Site
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84107
        • GSK Investigational Site
    • Virginia
      • Norfolk, Virginia, Förenta staterna, 23502
        • GSK Investigational Site
      • Richmond, Virginia, Förenta staterna, 23294
        • GSK Investigational Site
    • Washington
      • Seattle, Washington, Förenta staterna, 98166
        • GSK Investigational Site
    • Wisconsin
      • Menomonee Falls, Wisconsin, Förenta staterna, 53051
        • GSK Investigational Site
      • Milwaukee, Wisconsin, Förenta staterna, 53209
        • GSK Investigational Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 64 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion criteria:

  • Males with ED for more than six months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
  • Stable heterosexual relationship for more than 6 months.
  • The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary: Was sexual activity initiated with the intention of intercourse?) on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"]: Were you able to achieve at least some erection (some enlargement of the penis)? Were you able to insert your penis into your partner's vagina? Did your erection last long enough for you to have successful intercourse?
  • Diagnosis of dyslipidemia treated with a stable dose of a statin for 6 months at Visit 1.
  • IIEF-EF domain score of 25 denoting mild to severe ED at Visit 2.
  • Documented, dated, written Informed Consent.

Exclusion criteria:

  • Premature ejaculator <2 minutes
  • Any unstable medical, psychiatric, spinal cord injury, penile anatomical abnormalities, or substance abuse disorder that MD feels subject will not be able to complete the study.
  • Low sexual desire.
  • Prior prostatectomy surgery
  • Severe chronic or acute liver disease, history of moderate or severe liver impairment
  • Clinically significant chronic hematological disease
  • Bleeding disorder or significant active peptic ulceration.
  • Cardiovascular conditions that prevent sexual activity.
  • History of heart attack, stroke, or life-threatening arrhythmia within the prior 6 months.
  • hypotension or hypertension at rest.
  • cancer within the past 5 years. Use of these medications: nitrates or nitric oxide donors, anti-androgens, oral or injectable androgens, received any investigational drug (including placebo) within 30 days of screening (Visit 1).
  • Use of any treatment for ED within 7 days of screening including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
  • Subjects who are taking the following potent inhibitors of cytochrome P-450 3A4.

  • Abnormal Laboratory Values:

    1. serum total testosterone level >25% below the lower limit of normal
    2. serum creatinine >3.0 mg/dl.
    3. AST and/or ALT >3x the upper limit of normal.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: placebo
Läkemedel: placebo
placebo-jämförare
Aktiv komparator: Levitra
10mg x 4 weeks, with option to increase to 20mg aat that time if desired
Läkemedel: LEVITRA (vardenafil)
active comparator

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Erectile function (EF) domain score of the International Index of Erectile Function (IIEF)
Tidsram: Up to Week 12
The IIEF questionnaire is a validated 15-item instrument that assesses the participant's erectile function over the previous 4 weeks. The IIEF includes 5 domains affecting male sexual function: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Responses to the IIEF were re-coded using a standard coding method, where more positive responses received a higher score. The EF domain score was calculated as the sum of the re-coded scores from questions 1-5 and 15, using last observation carried forward (LOCF). Scores range from 1 (lowest) to 30 (highest). If two or more items in the EF domain were missing, the EF domain score was considered to be missing.
Up to Week 12
Mean success rate of insertion based on attempts
Tidsram: Up to Week 12
Success rate of insertion was derived from the Sexual Encounter Profile (SEP) Question 2 (SEP-2) of the participant's diary that asked 'Were you able to insert your penis into your partner's vagina?'. Responses were either Yes or No. Patients were instructed to complete diary questions as soon as possible after each sexual attempt, but no later than 24 hours after the attempt. The per-participant overall success rate for insertion was calculated by dividing the number of successful attempts (SEP-2=yes) over 12 weeks by the total number of valid attempts recorded over 12 weeks. If the participant was not able to make any valid attempts in 12 weeks, the participant was non-evaluable. Per-participant success rates were then averaged at the group level to obtain the mean success rate from Weeks 0-12.
Up to Week 12
Mean success rates of maintenance based on attempts
Tidsram: Up to Week 12
Success rate of maintenance was derived from the SEP Question 3 (SEP-3) of the participant's diary that asked 'Did your erection last long enough for you to have successful intercourse?'. Responses were either Yes or No. Participants were instructed to complete diary questions as soon as possible after each sexual attempt, but no later than 24 hours after the attempt. The per-participant overall success rate for maintenance was calculated by dividing the number of successful attempts (SEP-3=yes) over 12 weeks by the total number of valid attempts recorded over 12 weeks. If the participant was not able to make any valid attempts in 12 weeks, the participant was non-evaluable. Per-participant success rates were then averaged at the group level to obtain the mean success rate from Weeks 0-12.
Up to Week 12

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean duration of erection leading to completion of successful intercourse as measured by Sexual Encounter Profile Question 3 [SEP-3]
Tidsram: Up to Week 12
Duration of erection leading to completion of successful intercourse was derived from data recorded in the participant's diary. For each diary entry, the time from erection perceived hard enough for penetration until withdrawal from partner's vagina was measured by stopwatch and recorded in the participant's diary. For diary entries where SEP-3=yes, this recorded duration was used in calculations of a per-participant median duration. For diary entries where SEP-3=no, a duration of 0 was used to calculate the per-participant median. The per-participant median values averaged at the group level to obtain the mean duration of erection leading to completion of successful intercourse as measured by SEP-3.
Up to Week 12
Change from Baseline in scores for questions on the IIEF questionnaire and scores of the other non-EF domains of the IIEF
Tidsram: Up to Week 12
Non-EF domains of the IIEF (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, Overall Satisfaction) and IIEF questions (Erection during sexual activity?, Hard enough for penetration?, Able to penetrate partner?, Maintain your erection?, Maintain to completion?, Times attempted intercourse, Satisfactory for you?, Enjoyed sexual intercourse?, How often did you ejaculate?, How often feeling of orgasm?, How often felt sexual desire?, Rate level of sexual desire?, How satisfied with sex life?, Satisfied with sexual relationship? and Confidence to get, keep erection?) scores were assessed at Week 4, Week 8 and Week 12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.
Up to Week 12
Number of participants with normal erectile function having EF domain scores of 26 and above
Tidsram: Up to Week 12
The EF domain score was calculated by summing recoded responses to Questions 1-5 and 15, for each participant. It ranged from 1 to 30. EF domain scores were dichotomized as either normal (26 and above) or below normal (below 26) using LOCF, to calculate number of participants returning to normal erectile function. For the EF domain score the total was considered to be missing if 2 or more answers in the domain were missing.
Up to Week 12
Change from Baseline in participant's diary results
Tidsram: Up to Week 12
Electronic diaries were provided to participants. Participants were supposed to complete the diary questions as soon as possible after each sexual attempt but no later than 24 hours after the attempts. The diary questions (Ability to achieve at least some erection, Ability to insert penis into partner's vagina, Long enough erection having successful intercourse, Satisfied with the hardness of erection, Satisfied with this sexual experience, Ability to ejaculate) response rates were presented for Weeks 0-12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.
Up to Week 12
Mean duration of erection regardless of SEP-3 Response
Tidsram: Up to Week 12
Duration of erection was time from erection perceived hard enough for penetration (start stopwatch) until withdrawal from the partner's vagina (stop stopwatch) regardless of completion of successful intercourse. The data was presented for overall period from Week 0 to Week 12.
Up to Week 12
Change from Baseline in duration of erection leading to completion of successful intercourse.
Tidsram: Up to Week 12
Duration of erection was time from erection perceived hard enough for penetration (start stopwatch) until withdrawal from the partner's vagina (stop stopwatch) leading to completion of successful intercourse. The data was presented for overall period from Week 0 to Week 12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.
Up to Week 12
Number of participants with response 'Yes' for Global Assessment Question
Tidsram: Up to Week 12
The participants were asked to complete the self-administered Global Assessment Question. The question asked was 'has the treatment you have been taking over the past 4 weeks improved your erections'. The response was either Yes or No depending on comparison to participant's erections before their participation in this study. For the scale missing values remained missing.
Up to Week 12
Mean score for Keep It Simple (KIS) scale
Tidsram: Up to Week 12
The KIS scale was a self-reported visual analog scale (VAS) from 0 to 10 designed to assess erections as 'how do you grade your erections over the last 4 weeks?'. For the scale missing values remained as missing.
Up to Week 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

GlaxoSmithKline

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

22 maj 2006

Primärt slutförande (Faktisk)

17 maj 2007

Avslutad studie (Faktisk)

17 maj 2007

Studieregistreringsdatum

Först inskickad

21 september 2006

Först inskickad som uppfyllde QC-kriterierna

21 september 2006

Första postat (Uppskatta)

22 september 2006

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 augusti 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 augusti 2017

Senast verifierad

1 augusti 2017

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 106718

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Erektil dysfunktion

Kliniska prövningar på placebo

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Algeria

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera